C
CERo Therapeutics Holdings, Inc. (CERO)
OQB – Real Time Price. Currency in USD
0.03
0.00 (0.00%)
At close: Mar 27, 2026, 4:00 PM EDT
Get all premium features to the best stock analysis tool
OQB – Real Time Price. Currency in USD
0.03
0.00 (0.00%)
At close: Mar 27, 2026, 4:00 PM EDT
CERo Therapeutics Holdings, Inc., an immunotherapy company, focuses on advancing the development of engineered T cell therapeutics for the treatment of cancer. Its lead development candidate is CER-1236, an autologous T cell therapy candidate for the treatment of hematologic malignancies and solid tumors. The company was incorporated in 2021 and is based in South San Francisco, California.
| Name | Position |
|---|---|
| Dr. Kristen Pierce Ph.D. | Chief Development Officer |
| Dr. Lawrence Corey M.D. | Co-founder & Head of Scientific Advisory Board |
| Mr. Andrew Albert Kucharchuk M.B.A. | Chief Financial Officer |
| Mr. Christopher B. Ehrlich M.B.A. | CEO & Chair |
| Date | Type | Document |
|---|---|---|
| 2026-03-11 | 8-K | ea0280905-8k_cero.htm |
| 2026-01-07 | 8-K | ea0272086-8k_cero.htm |
| 2025-12-19 | 8-K | ea0270420-8k_cero.htm |
| 2025-12-05 | S-1 | ea0267089-s1_cero.htm |
| 2025-12-02 | 8-K | ea0267798-8k_cero.htm |
| 2025-11-28 | DEF 14A | ea0262220-02.htm |
| 2025-11-19 | 10-Q | ea0263826-10q_cerotherap.htm |
| 2025-11-17 | NT 10-Q | ea0265704-nt10q_cero.htm |
| 2025-10-16 | 8-K | ea0261237-8k_cero.htm |
| 2025-10-14 | 8-K | ea0260318-8k_cero.htm |